Last reviewed · How we verify

Buspirone + PAP therapy

VA Office of Research and Development · FDA-approved active Small molecule

Buspirone acts as a serotonin 5-HT1A receptor agonist to reduce anxiety, while PAP (positive airway pressure) therapy mechanically maintains airway patency during sleep to treat obstructive sleep apnea.

Buspirone acts as a serotonin 5-HT1A receptor agonist to reduce anxiety, while PAP (positive airway pressure) therapy mechanically maintains airway patency during sleep to treat obstructive sleep apnea. Used for Generalized anxiety disorder with comorbid obstructive sleep apnea.

At a glance

Generic nameBuspirone + PAP therapy
SponsorVA Office of Research and Development
Drug class5-HT1A receptor agonist (buspirone component); mechanical airway support device (PAP component)
Target5-HT1A receptor (buspirone); physical airway obstruction (PAP)
ModalitySmall molecule
Therapeutic areaPsychiatry / Sleep Medicine
PhaseFDA-approved

Mechanism of action

Buspirone selectively binds to and activates 5-HT1A receptors in the brain, reducing anxiety symptoms without the sedation or dependence associated with benzodiazepines. PAP therapy delivers pressurized air through a mask to prevent airway collapse during sleep, restoring normal breathing patterns and oxygen saturation. This combination addresses both anxiety and sleep-disordered breathing, which often co-occur.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: